TRVI vs. CRNX, ALVO, HCM, AMRX, CPRX, BHC, OGN, MIRM, XENE, and IBRX
Should you be buying Trevi Therapeutics stock or one of its competitors? The main competitors of Trevi Therapeutics include Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), HUTCHMED (HCM), Amneal Pharmaceuticals (AMRX), Catalyst Pharmaceuticals (CPRX), Bausch Health Cos (BHC), Organon & Co. (OGN), Mirum Pharmaceuticals (MIRM), Xenon Pharmaceuticals (XENE), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry.
Trevi Therapeutics vs. Its Competitors
Trevi Therapeutics (NASDAQ:TRVI) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.
In the previous week, Crinetics Pharmaceuticals had 9 more articles in the media than Trevi Therapeutics. MarketBeat recorded 10 mentions for Crinetics Pharmaceuticals and 1 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.96 beat Crinetics Pharmaceuticals' score of 0.42 indicating that Trevi Therapeutics is being referred to more favorably in the media.
95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 18.3% of Trevi Therapeutics shares are held by insiders. Comparatively, 4.6% of Crinetics Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Trevi Therapeutics has higher earnings, but lower revenue than Crinetics Pharmaceuticals. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Trevi Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500.
Trevi Therapeutics currently has a consensus target price of $20.88, indicating a potential upside of 211.10%. Crinetics Pharmaceuticals has a consensus target price of $69.50, indicating a potential upside of 117.87%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Trevi Therapeutics is more favorable than Crinetics Pharmaceuticals.
Crinetics Pharmaceuticals' return on equity of -30.95% beat Trevi Therapeutics' return on equity.
Summary
Trevi Therapeutics beats Crinetics Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Trevi Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Trevi Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TRVI) was last updated on 7/17/2025 by MarketBeat.com Staff
Free TRVI Stock Alerts